Our study carried out in elderly and multimorbid patients with acute coronary syndrome initially treated with ASS (100 mg per day) plus Clopidogrel (75 mg per day) was focused at Clopidogrel low-and non-responders. Moreover, we intended to clarify how far patients with reduced Clopidogrel response can profit by switching to Prasugrel.
Introduction
According to generally accepted standards patients with a recent occurrence of acute coronary syndrome (ACS) should have a dual antiplatelet therapy (DAPT) based on ASS plus P2Y 12 receptor antagonist continued for 12 months; following this, a single thrombocyte aggregation inhibitorpreferably acetylsalicylic acid (ASS) -should be maintained.
Limitations of a dual platelet inhibition with ASS plus Clopidogrel arise from a possible resistance to Clopidogrel, which may be found in 4 to over 30 percent (depending on the author) of all patients treated (1, 15, 17, 24, 28). On average, about every third patient shows resistance to Clopidogrel, about every fifth patient to ASS (19) . Resistance to ASS seems to have similar pejorative effects on the prognosis of subsequent cardiovascular incidents (29) , as resistance to P2Y 12 receptor antagonists (21) . In particular, the risks of subsequent recurrence of ACS and stent-thrombosis are increased (19, 14, 20) .
Patients proved to be Clopidogrel-resistant can be treated with newer P2Y 12 -receptorantagonists. Prasugrel is the first representative of this new generation of drugs. It is activated via only one stage of metabolism (31) , it reaches its level of efficiency faster and induces a stronger maximal platelet inhibition (31) . Genetic polymorphs of the Cytochrome isoenzymes have less inhibitory effect on the activation of Prasugrel than in the case of Clopidogrel (30) . Consequently, variations in efficiency from patient to patient are markedly less obvious than for Clopidogrel (9) .
According to manufacturers´ recommendations (published in Europe), elderly patients (≥ 75 year old) and patients of low weight (< 60 kg) should be given a half maintenance dose when treated with Prasugrel (5 mg instead of 10 mg). However, this reduction of dose is not generally accepted (and therefore not worldwide recommended up till now). As shown in the GENERATIONS trial, 5 mg Prasugrel lead to adequate platelet inhibition in 155 elderly patients with stabile angina pectoris (12).
In our study, 178 elderly patients with ACS are evaluated with regard to their Clopidogrel and Prasugrel response. Based on VASP tests, the efficiency of platelet inhibition achieved with Clopidogrel was compared with that achievable by switching to Prasugrel (5 or 10 mg) in those patients showing a limited Clopidogrel response. It was further evaluated, which responder rates can be achieved when such patients affected with a limited Clopidogrel response are switched to Prasugrel. Lastly, we examined whether differences of age, gender or influences of co-medications or comorbidity can be proved to affect Clopidogrel resistance. The aggregation inhibitory effect achieved with Prasugrel or Clopidogrel was evaluated in all of our patients and in several patient subgroups; all parameters measured were submitted to comparative statistical analyses. (25) . Especially the VASP-test showed a good correlation to stentthromboses (25, 16, 7) . A strong agreement between aggregation measurements with Verify Now and VASP-test could also be shown by Bidget et al. (5) . VASP-test and Verify Now also showed the best correlation with the plasma concentration of active Clopidogrel metabolites, so that these two tests were particularly recommended for monitoring Clopidogrelinduced platelet inhibition (10) . The VASP test has a very high prognostic value for ischemic events in patients undergoing treatment with P2Y 12 -receptor antagonists following PCI (26) .
Material and methods

Patient groups
In contrast to Verify Now, no fresh blood is necessary for a VASP text. Instead, 10 ml of blood can be drawn into standard citrate tubes, as are also used for routine diagnostics in clotting mechanisms. The specimens drawn can be stored at room temperature and can be processed within a time window of 48 hours.
In consideration of all aspects mentioned, we decided to use VASP test for evaluation of Clopidogrel and Prasugrel response.
Diagnostic workflow
VASP tests were carried out by the Center for Laboratory Diagnostics, Koblenz, Germany, based on the method described by Schwarz (27) . We used a standardized kit from the manufacturer Biocytex (PLT VASP/ P2Y 12 -test); this assay can be used in citrated full blood. Platelets were marked with an antibody coupled with FITC; analyses were made with a flow cytometer Canto II from Becton & Dickinson, Heidelberg, Germany. From each specimen five single analyses were carried out and averaged; variation coefficients were documented for quality control.
In a first phase of our experiment, the VASP-test used was calibrated for several months, using specimens from healthy subjects not under treatment with thrombocyte aggregation inhibitors. These measurements showed a good correlation to reference values given by the manufacturer; in healthy young people the standard value of Thrombocyte Reactivity Index (TRI) was 100%; in healthy elderly persons it could physiologically decrease to circa 70%.
In a second phase of test evaluation, repetitive TRI measurements were carried out in patients under Clopidogrel over a period of three following days.
The "cut-off" value of TRI, which indicates an insufficient aggregation inhibition, and thus a lack in response to the respective platelet inhibitor, was defined by Bonello as ≥ 50% (8, 6). Thus, an index of ≥ 50% shows by definition a non-responder.
Through our comparative measurements in identical patients we could, however, show that the VASP test is affected with a relevant variation of values measured -, in a range which is comparable with usual enzymatic tests in laboratory medicine. Thus, for instance, repeated measurements in the same person, beginning with a reactive index of 50%, could "spontaneously" be reduced by 10, corresponding to a value of 40%. Consequently we determined that TRI between 40% and 50% corresponds to a diagnostic "shady or grey area" or to a questionable responder status, and so we defined patients with measurements in this area as "low responders". Sufficient platelet inhibition under Clopidogrel (status of a definite responder) we thus categorized as a TRI ≤ 40%.
Following these evaluation phases we started with routine measurements in elderly ACS patients treated with P2Y 12 inhibitors over a period of two following years.
All patients in the study group were tested for thrombocyte-reactivity within the frame work of the routine lab-work on the day of admission. For this purpose, 10 ml of citrate blood (the usual "clotting monovette") were processed on the same day by a specialized laboratory. All specimens were taken in the morning between 7.00 and 9.00, the laboratory analyses were performed in the afternoon of the same day.
Clinical and therapeutic workflow
All patients with a recent ACS, who fulfilled the inclusion criteria, underwent a VASP-test on the day of admission to determine their responder status under the initially existent dual platelet inhibition with ASS plus Clopidogrel. Those patients with a TRI under 40% were accepted as definite Clopidogrel responders, so that the dual platelet inhibition was carried on unchanged.
All non-responders (reactivity index ≥ 50%) and also all low-responders (TRI 40% or more, but less than 50%) were changed to Prasugrel directly on receiving the test results. This switching was carried out as an individual therapeutic decision of the physician responsible for the patients care, based on the patient´s information and agreement. As only those patients were switched to Prasugrel who showed a limited Clopidogrel response and agreed with this modification of their medication based on an intensive personal conversation and individual medical advice, ethical approval was not necessary according to the given German law. On the first day, a loading dose of 60 mg Prasugrel was given, from the second day on, the specific maintenance dose. Patients under 75 years weighting more than 60 kg were given a daily maintenance dose of 10 mg, patients of 75 years or older, or weighting less than 60 kg were given a daily dose of 5 mg Prasugrel.
8-10 days after change of therapy a VASPtest was carried out as a check on low-and non-responders switched to Prasugrel. In this way it could be determined how many Clopidogrel low-or non-responders converted to responders through change to Prasugrel. In the subgroup of patients on 5 mg Prasugrel it could also be tested how effective this daily-half dose was as a practical alternative with regard to responder status. Those few patients who did not show an appropriate reactivity index in the therapeutic spectrum under 5 mg Prasugrel were dismissed with a recommendation to increase the daily dose to 10 mg and later carry out a further control of the reactivity index on an outpatient basis
The flow diagram in Fig. 2 gives an overview of the design and "work flow" of our study.
Fig. 2: "Work flow" of TRI measurements and drug switching
Statistical tests
Qualitative characteristics of the total group and of some sub-groups were tested for statistical significance using the Chi-Square-test. For quantitative statistic analyses (testing the significance of various quantitative deviations)
IBM ® SPSS ® Statistics Version 22 (recent upgrade for 2013) for MAC was used. The normal scatter was tested by the Kolmogorov-Smirnov-test. Differences between groups were analyzed using the T-test and Mann-Whitney-U-test.
Results
Basic results
The fractions of low-and non responders in the total group and four patient subgroups (75 years and above, 70 years and above, 70 up till 75 years, and 69 years or younger) are shown in Fig. 3 . It is clearly to see that the problem of Clopidogrel resistance remains highly relevant in patients of advanced age, independent of gender.
Fig. 3: Fractions of Clopidogrel low-and non-responders in several sub-groups of patients examined [%]
Of the total of 79 patients who were detected as non responders (N = 57) or low responders (N = 22), 46 patients (58 % of those affected) could be switched from Clopidogrel to Prasugrel during their stay in our clinic. In the sub-group of patients aged over 75 (N = 94) containing 33 nonresponders and 11 low-responders, 25 patients (56 %) could be switched to Prasugrel. The larger sub-group of patients aged 70 years and more contained 63 lowand non-responders (45 non-responders and 18 low-responders); of these, 36 patients (57 %) could be switched to Prasugrel.
The remaining low-and non-responders were not switched to Prasugrel, either because the patients themselves refused or they were dismissed from inpatient-care before completion. Nevertheless, all of these low-and non-responders who were not switched over by us were recommended to change to Prasugrel.
All in all, we did not see any complications associated with DAPT either in patients treated with Clopidogrel or in those patients who were switched to Prasugrel, in particular, we did not see any bleeding.
Change in the responder status after switching from Clopidogrel to Prasugrel
In the total of 46 patients who were switched from Clopidogrel to Prasugrel, a repeat check of the VASP-test was carried out 8-10 days after switching. From the measurements gained in this way, we could quantitatively derive all reductions of original TRI values achieved by switch to Prasugrel calculated in percent for all of these patients and subgroups mentioned above (see section 3.1). The results of these calculations are shown in Fig. 4 .
Fig. 4: Reductions of TRI achievable by drug switching from Clopidogrel to Prasugrel, evaluated in Clopidogrel low-and non-responders, calculated in percent and demonstrated for several categories of age range
In the total group the initial values of TRI determined in all low-and non-responders could be decreased by 57% on average (arithmetic mean) or by 63% (median). A similar reduction was also shown in the sub-group of patients of 70 years or above (reduction by 58 or 63 %, arithmetic mean and median). In the sub-group of patients aged 75 years or more, there resulted an average reduction of the originally measured reactivity indices by 53-54 % (median or arithmetic average). On the whole, no patient was noted where the switch from Clopidogrel to Prasugrel had switch from Clopidogrel to Prasugrel had not caused a reduction in the reactivity indices originally measured. Thus, the entire low-and non-responders could reduce their initially measured values by switching to Prasugrel.
In spite of this favorable effect, a total of six patients was noted who could not be brought into a responder status, as defined, by changing to Prasugrel. These cases are sketched briefly in Tab. 3.
Quantitative statistical analyses of the Thrombocyte Reactivity Indices (TRI) measured
An overview of all TRI measurements carried out is given in Fig. 5 . Obviously, patients showing a limited Clopidogrel response could be successfully converted to adequate platelet inhibition by switching to Prasugrel (p ≤ 0.0001). Significant ageand gender-dependent differences could not be proved.
For the subgroup of 46 Clopidogrel lowand non-responders, who could be switched to Prasugrel during the rehabilitation treatment, the relevant, originally measured TRI under Clopidogrel was 59.39 ± 1.72 %, SD: 11.7 %, median: 58%, range: 40-83 %. If the six patients previously mentioned, who did not achieve the so-defined responder status even after switching medication, were removed from the group, 40 definite Prasugrel responders remain. These showed under Prasugrel an average TRI of 20.6 ± 1.50 %, SD: 9.5 %, median: 19 %, range: 7-36. This corresponds to the average TRI under Clopidogrel response (19.08 ± 1.16 %). In the Clopidogrel low-and nonresponders who were younger than 75 years (N = 21), the average TRI original value under Clopidogrel was 58.33 ± 2.51 % (median: 58%, range: 45-82 %). In the corresponding patients who were 75 years or older (N = 25), there was an original value of 60.28 ± 2.39 % (median: 56 %, range: 40-83 %). These tiny differences in the measured values of both sub-groups were statistically not significant. After changing to Prasugrel (10 mg before 74 years, 5 mg over 75 years) the TRI was highly significantly reduced in both age groups (p ≤ 0.0001). In the under 75-yearolds, there was a TRI value of 23.38 ± 3.43 % (median: 17%, range: 7-56%). In those patients aged at least 75 years, the corresponding TRI was 25.48 ± 2.37% (median: 25 %, range: 7-56 %): The tiny numerical difference in TRI values of younger and older patients (23.38 versus 25.48 %) was statistically not significant. Thus, it may be deduced that at an age over 75 years, a daily dose of 5 mg Prasugrel can achieve the same measurable effect as a 10 mg dose in a younger patient.
Evaluation of Co-morbidity
Clopidogrel low-and non responders were not affected with simultaneous diseases in significantly higher proportions when compared with responders. Thus, none of the various co-diseases being immanent in the study group was associated with a higher proportion of non responders.
Discussion
According to our findings, up to 50 % of elderly patients who survived ACS are affected with a limited Clopidogrel response whereas only 6 % of patients switched to Prasugrel remain in a low-or non-responder status. The rate of Clopidogrel low-and non-responders does not decrease with increased age, but rather potentially increases. Men also seem to be more commonly affected, on the whole, by Clopidogrel resistance, than women. These trends, however, cannot be statistically confirmed as significant in the patient groups examined. Nevertheless, it can be derived from these findings that elderly patients suffering from ACS may have a significant benefit when treated with ASS plus new generation P2Y12 receptor antagonists instead of Clopidogrel so that they should be preferably treated by such a newer DAPT regime. In the future clinical outcome studies should be planned in order to confirm this plausible hypothesis.
As an essential result of the data collection presented, it can be noted that in all patients examined who had a decreased Clopidogrel response, a reduction in the thrombocyte reactivity index can be achieved by switching to Prasugrel -even in patients of advanced age beyond 70 or 75 years. This result corresponds with other findings evaluated on patients who were electively treated with coronary stents without running through a previous acute coronary syndrome (4) . The vast majority of "switched" patients can also per definitionem be moved from the low-or non-responder status to a responder status; only in a few individual cases no sodefined response can be achieved by drug switching (3 % low-and 3 % nonresponders). This finding corresponds with results of the ACAPULCO study (32) ; in this study, carried out with younger patients, up to 6 % non-responders were found under Prasugrel and up to 34 % under Clopidogrel.
It can also be deduced from our study that in the vast majority of aged patients with ACS, an effective response can be achieved using the reduced dose of 5 mg Prasugrel daily. The TRI values of the elderly rehabilitation patients treated with 5 mg correspond to those of the younger patients treated with 10 mg Prasugrel. This finding confirms corresponding results evaluated in 155 patients with stable coronary artery disease (GENERATIONS trial, 12). Moreover, Clopidogrel low-and non-responders can achieve aggregation inhibition of comparable standard to Clopidogrel responders through switching to Prasugrel.
Clopidogrel-drug interactions have been described by several authors (2, 3, 13, 22) . In our study group we compiled all comedications (see Table 2 ), but the design of our trial was not intended to establish such interaction. We recommend making further separate studies to evaluate drug interactions with sample specifically selected for that aim.
Although our patients were affected with several co-diseases, none of these diseases was associated with limited Clopidogrel response in a higher proportion when compared with responders. This finding can also be regarded as unexpected, too, because especially renal insufficiency and diabetes mellitus can modulate therapeutic effects of drugs and drug interactions in many cases. 
